Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

November 29, 2018 Group News

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke

Amsterdam, The Netherlands – 29 November 2018
read more

Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.

November 6, 2018 Group News

Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.

Amsterdam, The Netherlands – 06 November 2018
read more